A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma - Wikidata - awgldk - TriplyDB

A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma

A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma

http://www.wikidata.org/entity/Q33616544

about

A Second WNT for Old Drugs: Drug Repositioning against WNT-Dependent Cancers Metabotropic glutamate receptors: from the workbench to the bedside.Metabotropic glutamate receptor 1 (Grm1) is an oncogene in epithelial cells.Activation of the glutamate receptor GRM1 enhances angiogenic signaling to drive melanoma progression.Metabotropic glutamate receptor 1 mediates melanocyte transformation via transactivation of insulin-like growth factor 1 receptor.Non-canonical Smads phosphorylation induced by the glutamate release inhibitor, riluzole, through GSK3 activation in melanoma Chemical-genetic screen identifies riluzole as an enhancer of Wnt/β-catenin signaling in melanoma Metabotropic glutamate receptor 1 expression and its polymorphic variants associate with breast cancer phenotypes.Cancer as a channelopathy: ion channels and pumps in tumor development and progression Glutamate secretion and metabotropic glutamate receptor 1 expression during Kaposi's sarcoma-associated herpesvirus infection promotes cell proliferation.The Akt signaling pathway: an emerging therapeutic target in malignant melanoma.Therapeutic potential for phenytoin: targeting Na(v)1.5 sodium channels to reduce migration and invasion in metastatic breast cancer.Molecular pathways: dysregulated glutamatergic signaling pathways in cancer Osteosarcoma cell proliferation and survival requires mGluR5 receptor activity and is blocked by Riluzole.Riluzole prodrugs for melanoma and ALS: design, synthesis, and in vitro metabolic profiling.Functional effects of GRM1 suppression in human melanoma cells.Voltage-gated sodium channels and metastatic disease.The association between cancer and amyotrophic lateral sclerosis.Targeting Wnt pathways in disease.Blockade of voltage-gated sodium channels inhibits invasion of endocrine-resistant breast cancer cells Genetics of melanoma The mRNA-edited form of GABRA3 suppresses GABRA3-mediated Akt activation and breast cancer metastasis U1 Adaptor Oligonucleotides Targeting BCL2 and GRM1 Suppress Growth of Human Melanoma Xenografts In Vivo Glutamate signaling in benign and malignant disorders: current status, future perspectives, and therapeutic implications.Metabotropic glutamate receptor-1 contributes to progression in triple negative breast cancer.Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer.Metabotropic glutamate receptor 1 disrupts mammary acinar architecture and initiates malignant transformation of mammary epithelial cells.Disruption of GRM1-mediated signalling using riluzole results in DNA damage in melanoma cells.Role of the G Protein-Coupled Receptor, mGlu1, in Melanoma Development.Altered glutamine metabolism and therapeutic opportunities for lung cancer.The glutamate release inhibitor Riluzole decreases migration, invasion, and proliferation of melanoma cells Glutamatergic signaling in cellular transformation.The current management of brain metastasis in melanoma: a focus on riluzole.Exploiting ROS and metabolic differences to kill cisplatin resistant lung cancer.Metabotropic glutamate receptors in cancer.Riluzole is a radio-sensitizing agent in an in vivo model of brain metastasis derived from GRM1 expressing human melanoma cells.Molecular imaging of ectopic metabotropic glutamate 1 receptor in melanoma with a positron emission tomography radioprobe (18) F-FITM.Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies.Multifunctional albumin nanoparticles as combination drug carriers for intra-tumoral chemotherapy.Riluzole enhances ionizing radiation-induced cytotoxicity in human melanoma cells that ectopically express metabotropic glutamate receptor 1 in vitro and in vivo.

P2860

Q26739665-5864601F-B14E-40CB-90AB-4C52252B65AB Q30448778-75815C31-7B6C-4772-8D8A-E7EC8219F050 Q30570451-648FD19C-73F8-497F-B00C-B78AED585E6B Q33560677-C92733D7-A834-42C3-BB53-ACE76048C8E1 Q33769639-732D8E17-D6D7-480B-9CFA-568BA81B7951 Q34450728-989802EA-9BDE-42DB-AFD4-7338577D0E2D Q34603059-0E4826B8-19EE-4CBF-8119-81AA56DA7727 Q34904277-D725ECCC-75CE-432E-A7BC-FDB019EEAFD7 Q35184108-5F5FA3B4-E6F7-41B0-8D5E-2BC4B0BA218F Q35315503-45071C9F-112F-4DF3-A517-D7823EE64BFF Q35911227-DE280146-F84B-4C59-9584-985FE9C8714B Q36107167-9E4D3BD4-1927-4F61-8229-58D76D68FD32 Q36170150-0B786DB3-E427-4C66-8A08-0E528B92BE77 Q36288488-E1F3DC39-40AC-42EA-AA66-8A1BEA99A500 Q36390918-6B4194D2-3903-4C15-8923-4254CE95A02D Q36409682-A7B1CA5B-6B0E-4BA5-BD24-6E313C34E340 Q36430239-75CE36ED-12B7-4A5B-9093-ACA7373AD170 Q36487523-4CAC0526-725C-45EE-9CF0-7A45CC5360BC Q36506697-66999373-6395-4164-BD17-0FF1622BFD70 Q36525395-83BC49D1-0CD3-4026-9852-9D41CAE45586 Q36563659-530018A4-AB7A-414A-AAC6-4FC0A7DB715E Q36582294-7D60108A-D908-4FD1-B310-4C8EC02A9A59 Q36757152-6BBCAD2E-90C8-4C34-9215-08AE50946D22 Q37121338-177167F9-70AA-49F4-97EB-E018F65984DC Q37431333-8D90E188-063C-42A8-BDF7-4089023429D5 Q37502074-0B5266CE-B882-4475-B0FC-D70D18782AA2 Q37540105-FB8218F7-F871-4D32-AF28-073922B42D0F Q37626431-146DCAD4-0144-465E-BC39-B572AC7AB16E Q37627169-E77AEBC8-5694-47C5-B733-BDD969D9632A Q37673339-FAC28306-6BD6-4029-AC7C-405F26A7EEA7 Q37731451-F1DA7B70-6843-4B0E-A623-F11FD929419B Q37978409-15D83A9D-783A-46CE-AAAC-E7F25F597D83 Q38532696-B3068E72-23C0-4999-9E4E-4A9E3BCA480D Q38681744-0BCD8AF9-5829-47F9-9A8E-8AD3D31AA07C Q38741884-EA70DE56-152E-4A38-B2A4-BCA3A2F9577A Q38943348-79149F44-A4CA-4338-B482-DD8BA40BF4AE Q39014061-08D9E94C-D49C-441F-B469-6D7911B8590A Q39168954-3C5B7AAD-C1D1-43A8-9DA4-C24EA594C482 Q39180827-2EAD4038-B44E-4128-8AD7-34C08D051484 Q39591407-7DE0A59C-CAE6-43AC-A06C-87F25ADF88C3

P2860

A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma

http://www.wikidata.org/entity/Q33616544

description

2009 nî lūn-bûn

@nan

2009 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma

@ast

A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma

@en

type

label

A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma

@ast

A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma

@en

prefLabel

A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma

@ast

A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma

@en

P1433

Q33616544-C93D1BEE-61AD-4722-80A1-4F2201610306

P1476

Q33616544-14C7171E-62A6-448E-87B3-4DFC5ABEB5E5

P2093

Q33616544-0E2288E6-8C7A-443C-89CA-101290D41B71

Q33616544-176F7B10-60B4-4C83-B3F9-52F99853C6BF

Q33616544-4382388E-8D02-4CFB-8435-5F180CCBD976

Q33616544-530BF202-A1C2-41D8-9807-040BD0351ECC

Q33616544-72733DC8-1DA7-46D2-A1F9-8EBB1F3BEAF2

Q33616544-77D322D8-2584-4268-B04F-0A98B8C82AC9

Q33616544-7C1FA3C1-DCF7-4BEB-8DC7-75570F7185D7

Q33616544-90E1B815-CD83-4170-A609-F1A2123A87DA

Q33616544-B6416007-CCF2-455B-A0A8-415A3A9D0585

Q33616544-F676B6A0-706C-4CF8-8334-593AD497AC47

P2860

Q33616544-140FB843-1FBA-48E5-BB34-49A9E7051EA4

Q33616544-2D068E2A-BA6B-46FE-B96A-0626E011EC6B

Q33616544-42E9ABEB-1489-4FFC-8B25-4CB87593ACD7

Q33616544-6C65B5E0-C89A-41E2-B616-5780A2F1649A

Q33616544-763D7953-BE27-4237-9405-D8B9F7061E46

Q33616544-8FB3843E-F0D4-4860-8CE0-EA97A914E617

Q33616544-A232CBB0-EF6B-466E-9F0F-77F6F72A72F3

Q33616544-C9855FE3-F1D5-46E1-B199-B94653B45C7C

Q33616544-CC250D98-7A3B-4744-832A-3364F32CD6BE

Q33616544-CE215543-E168-43B7-BFDD-7C9C0B6701C4

P304

Q33616544-44A2408A-1616-4DAC-9027-F0978080DE9B

P31

Q33616544-56EEE5DD-9722-48F1-B07E-7ADEC9DEB0C6

P356

Q33616544-BDFB2939-DBAB-4DA9-B80F-08FED5DB3FF7

P407

Q33616544-6312114E-A0A3-47A8-91D7-C15C9ADCD2DE

P433

Q33616544-9551F24C-42E4-4083-8954-B79C44B864D1

P478

Q33616544-8C956657-2717-4B9D-998A-667D1D369F31

P577

Q33616544-2A360C4E-F73B-425E-A25E-3A537F76E0A7

P698

Q33616544-46B094EE-8D5A-428E-84EE-AD297574D255

P932

Q33616544-38AD3C6A-62BC-4241-9450-823E2B333232

P356

1078-0432.CCR-08-3303

P1433

Clinical Cancer Research

P1476

A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma

@en

P2093

Anthony Yudd

http://www.w3.org/2001/XMLSchema#string

Dana Yip

http://www.w3.org/2001/XMLSchema#string

James S Goydos

http://www.w3.org/2001/XMLSchema#string

Janice A Mehnert

http://www.w3.org/2001/XMLSchema#string

Jeffery Kempf

http://www.w3.org/2001/XMLSchema#string

Jonathan H Lee

http://www.w3.org/2001/XMLSchema#string

Joseph L-K Chan

http://www.w3.org/2001/XMLSchema#string

Maithao N Le

http://www.w3.org/2001/XMLSchema#string

Suzie Chen

http://www.w3.org/2001/XMLSchema#string

Weichung J Shih

http://www.w3.org/2001/XMLSchema#string

P2860

Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma

Stimulation of oncogenic metabotropic glutamate receptor 1 in melanoma cells activates ERK1/2 via PKCepsilon.

Detection of B-RAF and N-RAS mutations in human melanoma.

Metabolic flare: indicator of hormone responsiveness in advanced breast cancer.

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).

Riluzole serum concentrations in patients with ALS: associations with side effects and symptoms.

New ideas for therapy in ALS.

Utility of preoperative [(18)]f fluorodeoxyglucose-positron emission tomography scanning in high-risk melanoma patients.

Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia.

Flare response in 18F-fluoride ion PET bone scanning.

P304

3896-3902

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-08-3303

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2009-05-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19458050

http://www.w3.org/2001/XMLSchema#string

P932

2812866

http://www.w3.org/2001/XMLSchema#string